[Utility and prognostic value of PET/CT, bone marrow biopsy and aspirate for detection of bone marrow involvement in diffuse large B-cell lymphoma]

Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):663-667. doi: 10.3760/cma.j.issn.0253-2727.2022.08.008.
[Article in Chinese]

Abstract

Objective: This study aimed to determine the value of bone marrow biopsy (BMB) , bone marrow aspiration (BMA) , and positron emission tomography combined with computed tomography (PET/CT) in bone marrow (BM) involvement and prognosis evaluation in diffuse large B-cell lymphoma (DLBCL) . Methods: The clinical data of patients with DLBCL who underwent PET/CT, BMB, and BMA of the iliac crest were retrospectively analyzed in Peking Union Medical College Hospital from January 2015 to November 2017. The BM involvement on PET/CT was defined as the ratio of maximal standardized uptake values of iliac crest BM to liver parenchyma intensity ≥1. Results: A total of 76 patients without liver involvement were enrolled, there were 32 males, and the median age was 53 (17-79) . Moreover, 16 patients (21.1%) had BM involvement on PET/CT, 12 (15.8%) had positive BMB, and 13 (17.1%) had positive BMA. Excellent correlation between BMA and BMB (κ=0.943) was found, including good correlation between PET/CT and BMB/BMA (κ=0.763 and 0.776, respectively) . After a median follow-up of 52 (0-82) months, BM involvement by BMB (P=0.037) and BMA (P=0.007) were poor prognostic factors for overall survival, positive PET/CT had no significant effect on prognosis (P>0.05) . Conclusion: PET/CT, BMB, and BMA are effective methods to detect BM involvement with great concordance. However, iliac crest BMB and BMA showed superior performance in prognosis evaluation.

目的: 探索PET/CT、骨髓活检(BMB)、骨髓涂片(BMA)在评估弥漫大B细胞淋巴瘤(DLBCL)骨髓侵犯中的作用及预后价值。 方法: 回顾性分析2015年1月至2017年11月于北京协和医院确诊,且同时具有PET/CT、BMB、BMA结果的DLBCL患者的临床资料。髂骨骨髓SUVmax与正常肝脏组织SUVmax比值≥1为诊断PET/CT骨髓受累的标准。 结果: 共纳入76例患者,男32例,中位年龄53(17~79)岁。PET/CT阳性者16例,BMB阳性者12例,BMA阳性者13例。BMB与BMA在诊断DLBCL骨髓侵犯方面具有良好一致性(κ=0.943),PET/CT与BMB(κ=0.763)及BMA(κ=0.776)的一致性略差。中位随访52(0~82)个月,BMB及BMA阳性是总生存的不良预后因素(P值分别为0.037和0.007),PET/CT阳性对预后无明显影响(P值均>0.05)。 结论: PET/CT、BMB、BMA对于诊断DLBCL骨髓侵犯具有较好的一致性,均为有效的检测手段。BMB和BMA的预后判断价值优于PET/CT。.

Keywords: Bone marrow aspirate; Bone marrow biopsy; Lymphoma, large B-cell, diffuse; Positron emission tomography combined with computed tomography.

Publication types

  • English Abstract

MeSH terms

  • Biopsy
  • Bone Marrow / pathology
  • Fluorodeoxyglucose F18
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / diagnosis
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography* / methods
  • Positron-Emission Tomography
  • Prognosis
  • Retrospective Studies

Substances

  • Fluorodeoxyglucose F18